Plasmablastic Lymphoma

Malignant lymphoma composed of large B lymphoid cells which have the immunophenotype of plasma cells and a predilection for the ORAL CAVITY.

Also Known As:

Plasmablastic Diffuse Large B-cell Lymphoma; Plasmablasts Diffuse Large B-cell Lymphoma; Lymphoma, Plasmablastic; Lymphomas, Plasmablastic; Plasmablastic Diffuse Large B cell Lymphoma; Plasmablastic Lymphomas; Plasmablasts Diffuse Large B cell Lymphoma

Networked: 169 relevant articles (19 outcomes, 3 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	T-Cell Lymphoma (Lymphoma, T Cell)
3.	Leukemia
4.	B-Cell Lymphoma (Lymphoma, B Cell)
5.	Lymphoma (Lymphomas)

Experts

1.	Castillo, Jorge J: 10 articles (01/2022 - 01/2010)
2.	Montes-Moreno, Santiago: 4 articles (01/2021 - 10/2012)
3.	Medeiros, L Jeffrey: 3 articles (10/2020 - 08/2015)
4.	Chen, Weina: 3 articles (10/2019 - 06/2011)
5.	Bibas, Michele: 3 articles (01/2019 - 12/2010)
6.	Wang, Huan-You: 3 articles (11/2016 - 06/2011)
7.	Udden, Mark M: 3 articles (01/2016 - 02/2002)
8.	Chen, Bo-Jung: 2 articles (08/2022 - 03/2020)
9.	Chuang, Shih-Sung: 2 articles (08/2022 - 03/2020)
10.	Dittus, Christopher: 2 articles (01/2022 - 01/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Plasmablastic Lymphoma:

1.	Bortezomib (Velcade)FDA Link 01/01/2022 - "[Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH]." 09/01/2019 - "Incorporating Bortezomib in the Management of Plasmablastic Lymphoma." 01/01/2019 - "Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma." 11/01/2017 - "Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease." 03/01/2016 - "Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma."
2.	Lenalidomide (CC 5013)FDA Link 01/01/2015 - "Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma." 10/01/2016 - "Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings." 01/01/2017 - "A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy." 01/01/2021 - "Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide." 01/01/2020 - "Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma."
3.	Vincristine (Oncovin)FDA LinkGeneric 01/01/2020 - "After 8 years, he developed gingival plasmablastic lymphoma treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone regimen with subsequent remission. " 01/01/2022 - "To describe the clinical profile and outcome of patients with HIV-associated plasmablastic lymphoma (PBL) treated with cyclophosphamide, doxorubicin, oncovin, prednisone (CHOP) chemotherapy in a tertiary hospital in KwaZulu-Natal, South Africa. " 06/01/2016 - "Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib." 01/01/2018 - "Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis." 10/01/2014 - "Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review."
4.	Prednisone (Sone)FDA LinkGeneric 01/01/2020 - "After 8 years, he developed gingival plasmablastic lymphoma treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone regimen with subsequent remission. " 01/01/2022 - "To describe the clinical profile and outcome of patients with HIV-associated plasmablastic lymphoma (PBL) treated with cyclophosphamide, doxorubicin, oncovin, prednisone (CHOP) chemotherapy in a tertiary hospital in KwaZulu-Natal, South Africa. " 06/01/2016 - "Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib." 01/01/2018 - "Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis." 10/01/2014 - "Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review."
5.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/01/2020 - "After 8 years, he developed gingival plasmablastic lymphoma treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone regimen with subsequent remission. " 01/01/2022 - "To describe the clinical profile and outcome of patients with HIV-associated plasmablastic lymphoma (PBL) treated with cyclophosphamide, doxorubicin, oncovin, prednisone (CHOP) chemotherapy in a tertiary hospital in KwaZulu-Natal, South Africa. " 06/01/2016 - "Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib." 01/01/2018 - "Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis." 10/01/2014 - "Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review."
6.	Dexamethasone (Maxidex)FDA LinkGeneric 06/08/2018 - "A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report." 01/01/2022 - "Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach." 01/01/2022 - "Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature." 12/01/2010 - "Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone."
7.	Rituximab (Mabthera)FDA Link 02/01/2012 - "For example, plasmablastic lymphoma typically lacks CD20 and does not benefit from treatment with rituximab. " 10/01/2014 - "Further large sample studies incorporating rituximab-based chemotherapy and more aggressive chemotherapy for plasmablastic lymphoma will be helpful for better understanding of treatment outcome." 07/01/2014 - "CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab." 01/01/2014 - "Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosa-associated lymphoid tissue lymphoma: a case report and review of literature."
8.	AntibodiesIBA 11/01/2005 - "The present study suggests that (i) CD117 expression can be detected sporadically in DLBCL of follicle center-cell origin and a subset of plasmablastic lymphomas; (ii) staining for CD117 might help in identifying EBV- plasmablastic lymphomas associated with bone marrow involvement; and (iii) CD117 antibodies should be carefully validated prior to use, because non-specific staining, as observed with Ab-1, could lead to false-positive results." 11/01/2005 - "The CD117 expression in DLBCL was further evaluated using tissue microarrays and seven additional plasmablastic lymphomas, using two commercially available anti-CD117 antibodies (Ab-1, Oncogene and A4502, DakoCytomation). "
9.	Thalidomide (Thalomid)FDA Link 06/08/2018 - "A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report." 10/01/2014 - "Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review."
10.	NucleosidesIBA 06/01/2017 - "Several nucleoside analogs are effective in treating leukemias and T cell lymphomas, and 6-ETI may fill this niche for the treatment of PEL, plasmablastic lymphoma, MM, and other ADK-expressing cancers."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2011 - "Orbital plasmablastic lymphoma with remission following chemotherapy." 11/01/2020 - "Herein we analyzed survival outcomes in chemotherapy-treated patients with plasmablastic lymphoma (PBL) diagnosed between 2010 to 2016 (n = 248). " 01/01/2020 - "Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy." 11/01/2016 - "Plasmablastic lymphoma was diagnosed, patient was treated with chemotherapy, and post treatment CT demonstrated complete resolution. " 08/01/2015 - "Patients with plasmablastic lymphoma usually have a poor prognosis despite aggressive chemotherapy. "
2.	Therapeutics 12/01/2019 - "Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone." 01/01/2022 - "Therapy related complications in plasmablastic lymphoma in immunocompetent individual." 01/01/2021 - "Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use." 06/01/2017 - "Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy." 10/01/2015 - "The clinical feature, pathogenesis, diagnosis, therapy and prognosis of primary cardiac plasmablastic lymphoma were further investigated through literatures review. "
3.	Highly Active Antiretroviral Therapy (HAART) 09/01/2016 - "Impact of highly active antiretroviral therapy in the development and remission of oral plasmablastic lymphoma." 09/01/2004 - "Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases." 11/15/2020 - "HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients: Erratum." 10/01/2020 - "HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients." 01/01/2016 - "Plasmablastic lymphoma is treatable in the HAART era. "
4.	Radiotherapy 01/01/2010 - "He was diagnosed as a plasmablastic lymphoma; radiation therapy (RT) was started, but the response to the RT was only a partial response. " 01/01/2010 - "HAART in addition to chemotherapy and/or radiotherapy is effective in improving the prognosis of plasmablastic lymphoma. " 10/01/2021 - "Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer." 01/01/2010 - "Meta-analysis result showed that the prognosis of plasmablastic lymphoma patients was statistically different in the patients receiving HAART in addition to chemotherapy and/or radiotherapy than in the patients receiving the chemotherapy and/or radiotherapy alone (pooled relative risk=3.04; P=.03). " 03/01/2016 - "Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review."
5.	Stem Cell Transplantation 03/30/2011 - "Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy." 01/01/2007 - "AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A." 06/08/2018 - "A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report." 03/30/2011 - "We successfully performed autologous stem cell transplantation using a regimen consisting of MCNU (ranimustine), etoposide, cytarabine, and melphalan in a Japanese patient with relapsed AIDS-related plasmablastic lymphoma of the oral cavity. "